AstraZeneca Launches Phase III Trials Testing Novel Immunotherapy Rilvegostomig in Lung and Breast Cancers

AstraZeneca查看公司主页 has launched two pivotal Phase III clinical trials to evaluate rilvegostomig查看药品详情 (AZD2936查看药品详情), an experimental immunotherapy agent, in combination therapies for breast and lung cancers. The trials represent a significant investment in advancing novel immunotherapy combinations beyond current standard-of-care treatments.

Breast Cancer Combination Trial

The first Phase III study (D781DC00001) is testing rilvegostomig查看药品详情 in combination with trastuzumab deruxtecan查看药品详情 (T-DXd查看药品详情, DS-8201a查看药品详情) for breast cancer (搜索)搜索该疾病 patients. The trial features a three-arm design comparing different therapeutic approaches.

Arm A evaluates T-DXd查看药品详情 plus rilvegostomig查看药品详情 administered intravenously every three weeks (Q3W). Arm B tests T-DXd combined with pembrolizumab查看药品详情 (Keytruda查看药品详情), also given Q3W. The active comparator arm (Arm C) uses the established regimen of carboplatin查看药品详情, paclitaxel查看药品详情, and pembrolizumab administered Q3W for six cycles, followed by pembrolizumab maintenance therapy every six weeks for 14 cycles.

Treatment in the experimental arms will continue until objective disease progression according to RECIST v1.1 criteria as assessed by investigators and confirmed by blinded independent central review (BICR), or until other discontinuation criteria are met. The control arm allows for pembrolizumab查看药品详情 treatment for up to 20 total cycles, approximately 24 months including both combination and maintenance phases.

Lung Cancer Platform Study

The second Phase III trial (D702FC00001) focuses on lung cancer (搜索)搜索该疾病 patients and directly compares rilvegostomig查看药品详情 against pembrolizumab查看药品详情, both in combination with platinum-based chemotherapy. This head-to-head comparison represents a direct challenge to the current immunotherapy standard of care.

Arm A combines rilvegostomig查看药品详情 with platinum-based doublet chemotherapy (carboplatin查看药品详情 or cisplatin查看药品详情 plus pemetrexed查看药品详情) for up to four cycles, followed by rilvegostomig monotherapy plus pemetrexed maintenance. The active comparator Arm B uses the established pembrolizumab查看药品详情 regimen with the same chemotherapy backbone and maintenance approach.

Both treatment regimens follow a 21-day cycle schedule with intravenous administration on Day 1 of each cycle. The platinum agents (carboplatin查看药品详情 or cisplatin查看药品详情) are limited to four cycles, while the immunotherapy agents and pemetrexed查看药品详情 continue in the maintenance phase.

Treatment Flexibility and Safety Considerations

The breast cancer (搜索)搜索该疾病 trial incorporates treatment flexibility to address potential safety concerns. Investigators may extend the carboplatin查看药品详情, paclitaxel查看药品详情, and pembrolizumab查看药品详情 combination for up to 10 cycles at their discretion. Additionally, docetaxel查看药品详情 can substitute for paclitaxel in patients who experience hypersensitivity reactions that cannot be successfully rechallenged.

Strategic Implications

These Phase III trials position rilvegostomig查看药品详情 as a potential competitor to pembrolizumab查看药品详情, one of the most successful immunotherapy agents in oncology. The direct comparison design in the lung cancer (搜索)搜索该疾病 study and the inclusion of pembrolizumab arms in the breast cancer (搜索)搜索该疾病 trial provide clear benchmarks for evaluating rilvegostomig's therapeutic potential.

The trials' focus on combination therapies reflects the current trend in oncology toward multi-modal treatment approaches. By pairing rilvegostomig查看药品详情 with established agents like trastuzumab deruxtecan查看药品详情 and platinum-based chemotherapy, AstraZeneca查看公司主页 is positioning the drug within proven therapeutic frameworks while potentially offering improved efficacy or tolerability profiles.